Navigation Links
Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
Date:6/15/2009

The Company's unaudited interim Consolidated Statements of Operations and Cash Flows for the three and nine month periods ended April 30, 2009 and 2008 are summarized below:

    Consolidated Statements of Operations
    for the three and nine month periods ended April 30, 2009 and 2008
    ($ thousands, except for per share data)

                                          Three months         Nine months
                                         ended April 30       ended April 30
                                         2009      2008       2009      2008
    Revenue:
     Product revenue                      793       775      2,454     2,181
     License fees and royalties           131       243        452       513
                                          924     1,018      2,906     2,694
    Expenses:
     Cost of sales                        375       326      1,160       908
     Research and development           3,082     1,068      7,584     2,879
     Operating, general and admin       1,231     1,060      3,854     3,618
     Amortization of intangible assets      3         3          9        13
     Amortization of capital assets        64        61        191       190
     Stock-based compensation             234        12        865        36
     Interest income, net                 (27)     (180)      (332)     (465)
     Foreign exchange loss / (gain)        67      (220)       199      (265)
                                        5,029     2,130     13,530     6,914


    Loss before income taxes           (4,105)   (1,112)   (10,624)   (4,220)

    Income taxes                           29        27         83        89

    Loss for the period                (4,134)   (1,139)   (10,707)   (4,309)

        Loss per share:
         Basic                          (0.08)    (0.03)     (0.21)    (0.11)
         Diluted                        (0.08)    (0.03)     (0.21) 
'/>"/>
SOURCE  Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 

Related biology technology :

1. Helix Biopharma announces addition of University of Arizona professor Kenneth Hatch as new medical advisor
2. Helix BioPharma Chairman resigns
3. Helix BioPharma Corp. announces fiscal 2007 results
4. Helix BioPharma Corp. announces management changes
5. Helix BioPharma announces $16.9 million private placement of common shares
6. Helix BioPharma announces Q1 2008 financial results
7. Helix BioPharma closes $16.9 million private placement of common shares
8. Helix BioPharma Corp. contracts KBI Biopharma to develop an L-DOS47 clinical packaging format
9. Helix BioPharma shareholders vote in favour of management
10. Helix BioPharma reports Q2 2008 highlights, financial results
11. W. Thomas Hodgson appointed to board of Helix BioPharma Corp.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 NANONEX CORPORATION, a pioneer ... today announced the successful delivery and installation of ... NX-M200B, to a major Japanese manufacturing company. ... production-ready, advanced nanoimprint lithography tool that has the ... substrate sizes and types. Based on Nanonex inventions ...
(Date:5/21/2013)... May 21, 2013 Possible mold re-infestation in ... according to a report from eagletribune.com posted May 14, 2013, ... case the result is positive, My Cleaning Products offered a ... chemical ingredients. , It was said in the Eagle Tribune ... in the campus sparked after a first-grade classroom was closed ...
(Date:5/21/2013)... The Formulate Fusion Fabric Display Kit ... marketing teams looking for a fully-functional package for their trade ... you’ll need to put together a stunning and eye-catching trade ... number of displays and accessories that can be quickly assembled ... feet in size. These components vary from kit to kit, ...
(Date:5/20/2013)... 21, 2013 Grace Century , ... “game-changing” life science and health related private equity projects, ... its International Project Team. Dergham's expertise in finance and ... depth to Grace Century as it continues to look ... Ms. Dergham holds both an under graduate degree from ...
Breaking Biology Technology:Nanonex Announces the Shipment and Installation of an Innovative Nanoimprint Lithography System for Fully Automated Manufacturing 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 3GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2Dalia Dergham Joins Grace Century FZ LLC International Project Team 2
... Adhere to Sleep Apnea TreatmentSAN CARLOS, Calif., Feb. ... study has shown their patients comply with Obstructive ... the industry average.Analysis performed in October 2008 looked ... testing and treatment with Positive Airway Pressure beginning ...
... 3 BioMarin Pharmaceutical Inc. (Nasdaq: ... 2 multi-center, randomized, double-blind, placebo-controlled clinical study of ... (PAD). There was no statistical significance observed ... endpoint of the study, peak walking time (PWT), ...
... Bulletin Board: AGGX.OB) is a New York-based biotechnology company ... proteins for the discovery and development of anti-angiogenic drugs ... presented animal data at two recent scientific ... molecule candidate drug AGX51 to mitigate tumor formation and ...
Cached Biology Technology:SleepQuest Compliance Again Doubles Industry Average 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 2Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 3Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant 4AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences 2AngioGenex Presents Data on its Id Targeted Anti-Angiogenesis Inhibitors at Two Scientific Conferences 3
(Date:5/18/2013)... MD (May 19, 2013) The AGA Research Foundation ... and Damian Augustyn Award in Digestive Cancer, which will ... of Medicine at the University of Pennsylvania, Philadelphia, as ... in pancreas development, regeneration and cancer progression. , "The ... in honor of two distinguished clinicians and AGA Legacy ...
(Date:5/17/2013)... day, insects provide the white noise of the South, but ... year, the Southern air hangs heavy from the humidity and ... more than 140 species of frogs, toads and salamanders, is ... the ponds and swamps are the auditorium for their symphonic ... and Monitoring Initiative, or ARMI, have front-row seats. ...
(Date:5/17/2013)... iCargo project (Intelligent Cargo in Efficient and Sustainable Global ... to an improvement in the efficiency of intermodal loading ... decision making. It comprises 29 European organisations with experience ... It has a budget totalling 17,000,000 and a duration ... working to specify and develop the semantic components and ...
Breaking Biology News(10 mins):AGA Research Foundation grant furthers digestive cancer research 2Front-row seats to climate change 2Front-row seats to climate change 3Front-row seats to climate change 4New logistics services that will cut energy consumption and CO2 emissions 2
... days shortening toward winter, many people will begin to experience ... About 6 percent of the U.S. population suffers ... begins in the fall and continues through winter. Sufferers may ... the morning. The disorder, which is not well understood, ...
... look at that cheap piece of scrap iron before you ... good use for it. Someday soon, much of the world ... engineering, recently concluded a five-year research project in which he ... million pounds of iron to detoxify pollutants in industrial wastewater. ...
... and simulation experts from Rhode Island Hospital discuss ... manuscripts appearing in the November 2008 issue of ... The articles describe how simulation centers, along with ... for dynamic, complex and unanticipated medical situations in ...
Cached Biology News:Seasonal affective disorder may be linked to genetic mutation, study suggests 2A green future for scrap iron 2A green future for scrap iron 3Rhode Island Hospital simulation center examines benefits and applications of medical simulation 2Rhode Island Hospital simulation center examines benefits and applications of medical simulation 3
Sf21 cells derived from Spodoptera frugiperda ovarian cells are recommended for high-level production of recombinant proteins. Higher expression levels of some proteins are seen due to the larger ce...
... The steadylite plus assay ... High assay sensitivity, Designed for ... Suitable for higher density microplates ... plates, Odor free, Convenient storage ...
Sf9 cells derived from Spodoptera frugiperda ovarian cells (Sf21 cells) are commonly used to isolate and propagate recombinant AcMNPV viral stocks and to produce recombinant proteins....
Functionally tested for consistent G-banding of chromosomes....
Biology Products: